1. Kozlov M.. Does omicron hit kids harder? Scientists are trying to find out. Nature 2022 February 4 (Epub ahead of print).
2. ShiDS, Whitaker M, Marks KJ, et al. Hospitalizations of children aged 5–11 years with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 2020–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:574–581.
3. Nearchou F, Flinn C, Niland R, Subramaniam SS, Hennessy-E. Exploring the impact of COVID-19 on mental health outcomes in children and adolescents: a systematic review. Int J Environ Res Public Health 2020;17:8479–8479.
4. Meherali S, Punjani N, Louie Poon S, et al. Mental health of children and adolescents amidst COVID-19 and past pandemics: a rapid systematic review. Int J Environ Res Public Health 2021;18:3432–3432.
5. Ministry of Health Singapore. Vaccination statistics. February 22, 2022 (https://www.Moh.Gov.Sg/Covid-19/Vaccination/Statistics).
6. GISAID. Tracking of variants: VOC omicron GRA (B.1.1.529+Ba.*) first detected in Botswana/Hong Kong/South Africa. February 2022 (https://www.Gisaid.Org/Hcov19-Variants/).
7. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med 2022;386:35–46.
8. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021;385:239–250.
9. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021;385:1393–1400.
10. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–1423.
11. Jara A, Undurraga EA, Flores JC, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. February 15, 2022 (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4035405). preprint.
12. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2022;602:671–675.
13. Hoffman M, Kruger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 2022;185(3):447.e11–456.e11.
14. Have J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune will be elicited by vaccines after boost. Emerg Infect Microbes 2022;11:337–343.
15. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 years — VISION Network, 10 states, April 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:352–358.
16. Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years — PROTECT cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:422–428.
17. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:255–263.
18. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:139–145.
19. Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med 2022;386:1899–1909.
20. Health Sciences Authority of Singapore. HSA’s Covid-19 vaccine safety update #11 (30 December 2020–28 February 2022). 2022 (https://www.Hsa.Gov.Sg/Docs/Default-Source/Hprg-Vcb/Safety-Update-On-Covid19-Vaccines/Hsa-Safety-Update-No-11-On-Covid-19-Vaccines- (28-February-2022).PDF).
21. Feldstein LR, Tenford MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021;325:1074–1087.
22. Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolescent Health 2021;5:708–718.
23. Dattner I, Goldberg Y, Katriel G, et al. The role of children in the spread of COVID-19: using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. PLoS Comput Biol 2021;17(2):e1008559–e1008559.
24. Hudson A., Montelpare WJ. Predictors of vaccine hesitancy: implications for COVID-19 public health messaging. Int J Environ Res Public Health 2021;18:8054–8054.
25. Payne PR, Longet S, Austin J.A., et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 2021;184(23):5699.e11–5714.e11.
26. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci 2022;37(5):e35–e35.
27. Ward J.L., Harwood R, Smith C, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. NatMed 2022;28:193–200.
28. Wong JJM, Abbas Q, Chuah SL, et al. Comparative analysis of pediatric COVID-19 infection in Southeast Asia, South Asia, Japan, and China. Am J Too Med Hyg 2021;105:413–420.
29. Grivá K, Tan KYK, Chan FHF, et al. Evaluating rates and determinants of COVID-19 vaccine hesitancy for adults and children in the Singapore population: Strengthening Our Community’s Resilience against Threats from Emerging Infections (SOCRATEs) cohort. Vaccines (Basel) 2021;9:1415–1415.
30. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Say Child 2020;106:429–439.
31. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis 2022;116:38–42.
32. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126–2128.
33. Marks KJ, Whitaker M, Agathis NT, et al. Hospitalization of infants and children aged 0–4 years with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 2020–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:429–436.